ERBB3 and head and neck squamous cell carcinoma: This differential phosphorylation of EGFR1, HER2, and HER3 in HNSCC and MOE1b and MOE1a cells, and the distinct effects of afatinib on downstream signaling pathways might explain its differential efficacy and toxicity on HNSCC and normal cells.